NDRA (ENDRA Life Sciences Inc) רווח למניה בשנים עשר החודשים האחרונים

ENDRA Life Sciences is currently refining its clinical approaches to comply with US regulatory standards. The year-over-year EPS (TTM) comparison visualizes this transformation period, where 97.80 shows the value of this parameter. Profitability relies on the integration of TAEUS systems into hepatology practice, while diagnostic accuracy is ensured by automated signal processing algorithms that minimize human error.
NDRA (ENDRA Life Sciences Inc.): פילוחים אנליטיים ודוחות לפי אינדיקטורים

Investors are assessing the resilience of ENDRA Life Sciences (NDRA) through the lens of its ability to scale profits amid the expansion of TAEUS systems into US clinics. The efficiency of capturing market share in diagnostic equipment is directly reflected in the growth rate of net earnings per share. By analyzing the annual EPS TTM dynamics, the user observes a rolling change in profitability without reporting gaps. This indicator reveals whether the asset is overheated or identifies hidden trend reversal points, while extreme peaks on the chart warn of a potential price correction risk.